Overview

An Effectiveness and Safety Study Comparing Oxybutynin Chloride Plus FLOMAX (Tamsulosin HCl) and Placebo Plus FLOMAX (Tamsulosin HCl) for the Treatment of Lower Urinary Tract Symptoms.

Status:
Completed

Trial end date:
2005-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and effectiveness of oxybutynin extended release tablets 10 mg plus tamsulosin HCl 0.4 mg in the treatment of lower urinary tract symptoms as measured by change of the total International Prostate Symptom Score (I-PSS) from baseline to Week 12 or the Final Visit.

Phase:

Phase 3

Details

Lead Sponsor:

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Treatments:

Mandelic Acids
Oxybutynin
Tamsulosin